nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—Corticosteroid Hormone Receptor Agonists—Prednisone—systemic scleroderma	0.213	1	CiPCiCtD
Methylprednisolone—Mometasone—systemic scleroderma	0.129	0.647	CrCtD
Methylprednisolone—osteoarthritis—Prednisone—systemic scleroderma	0.1	1	CpDpCtD
Methylprednisolone—ankylosing spondylitis—systemic scleroderma	0.0721	0.35	CtDrD
Methylprednisolone—Prednisone—systemic scleroderma	0.0703	0.353	CrCtD
Methylprednisolone—systemic lupus erythematosus—systemic scleroderma	0.0688	0.334	CtDrD
Methylprednisolone—rheumatoid arthritis—systemic scleroderma	0.0649	0.316	CtDrD
Methylprednisolone—NR3C1—Mometasone—systemic scleroderma	0.0495	0.527	CbGbCtD
Methylprednisolone—NR3C1—Prednisone—systemic scleroderma	0.0158	0.168	CbGbCtD
Methylprednisolone—ABCB1—Lisinopril—systemic scleroderma	0.00779	0.0829	CbGbCtD
Methylprednisolone—ABCB1—Captopril—systemic scleroderma	0.00583	0.0621	CbGbCtD
Methylprednisolone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00459	0.0489	CbGbCtD
Methylprednisolone—Flumethasone Pivalate—Mometasone—systemic scleroderma	0.00407	0.0277	CrCrCtD
Methylprednisolone—Difluprednate—Mometasone—systemic scleroderma	0.00394	0.0268	CrCrCtD
Methylprednisolone—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00394	0.0268	CrCrCtD
Methylprednisolone—Halobetasol Propionate—Mometasone—systemic scleroderma	0.00394	0.0268	CrCrCtD
Methylprednisolone—Exemestane—Prednisone—systemic scleroderma	0.00386	0.0263	CrCrCtD
Methylprednisolone—Fluocinonide—Mometasone—systemic scleroderma	0.0037	0.0252	CrCrCtD
Methylprednisolone—Clocortolone—Mometasone—systemic scleroderma	0.0037	0.0252	CrCrCtD
Methylprednisolone—Prednicarbate—Mometasone—systemic scleroderma	0.0037	0.0252	CrCrCtD
Methylprednisolone—Testolactone—Mometasone—systemic scleroderma	0.0037	0.0252	CrCrCtD
Methylprednisolone—ABCB1—Prednisone—systemic scleroderma	0.00367	0.0391	CbGbCtD
Methylprednisolone—Fluocortolone—Mometasone—systemic scleroderma	0.0036	0.0245	CrCrCtD
Methylprednisolone—Alclometasone—Mometasone—systemic scleroderma	0.0035	0.0238	CrCrCtD
Methylprednisolone—Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.0035	0.0238	CrCrCtD
Methylprednisolone—Budesonide—Mometasone—systemic scleroderma	0.0034	0.0231	CrCrCtD
Methylprednisolone—Flunisolide—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Fludrocortisone—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Diflorasone—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Desonide—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Clobetasol propionate—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Prednisone—Mometasone—systemic scleroderma	0.00331	0.0225	CrCrCtD
Methylprednisolone—Paramethasone—Mometasone—systemic scleroderma	0.00323	0.022	CrCrCtD
Methylprednisolone—Desoximetasone—Mometasone—systemic scleroderma	0.00315	0.0214	CrCrCtD
Methylprednisolone—Loteprednol—Mometasone—systemic scleroderma	0.00308	0.0209	CrCrCtD
Methylprednisolone—Fluorometholone—Mometasone—systemic scleroderma	0.00308	0.0209	CrCrCtD
Methylprednisolone—Triamcinolone—Mometasone—systemic scleroderma	0.00308	0.0209	CrCrCtD
Methylprednisolone—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.00308	0.0209	CrCrCtD
Methylprednisolone—Rimexolone—Mometasone—systemic scleroderma	0.00301	0.0205	CrCrCtD
Methylprednisolone—Betamethasone—Mometasone—systemic scleroderma	0.00301	0.0205	CrCrCtD
Methylprednisolone—Dexamethasone—Mometasone—systemic scleroderma	0.00301	0.0205	CrCrCtD
Methylprednisolone—Prednisolone—Mometasone—systemic scleroderma	0.00282	0.0192	CrCrCtD
Methylprednisolone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00275	0.0293	CbGbCtD
Methylprednisolone—Hydrocortisone—Mometasone—systemic scleroderma	0.0027	0.0184	CrCrCtD
Methylprednisolone—Ciclesonide—Prednisone—systemic scleroderma	0.00256	0.0174	CrCrCtD
Methylprednisolone—CYP3A4—Prednisone—systemic scleroderma	0.0022	0.0234	CbGbCtD
Methylprednisolone—Hydrocortamate—Prednisone—systemic scleroderma	0.00215	0.0146	CrCrCtD
Methylprednisolone—Cortisone acetate—Prednisone—systemic scleroderma	0.00208	0.0141	CrCrCtD
Methylprednisolone—Testolactone—Prednisone—systemic scleroderma	0.00202	0.0137	CrCrCtD
Methylprednisolone—Prednicarbate—Prednisone—systemic scleroderma	0.00202	0.0137	CrCrCtD
Methylprednisolone—Fluocortolone—Prednisone—systemic scleroderma	0.00196	0.0133	CrCrCtD
Methylprednisolone—Alclometasone—Prednisone—systemic scleroderma	0.00191	0.013	CrCrCtD
Methylprednisolone—Budesonide—Prednisone—systemic scleroderma	0.00185	0.0126	CrCrCtD
Methylprednisolone—ABCB1—Methotrexate—systemic scleroderma	0.00184	0.0196	CbGbCtD
Methylprednisolone—Diflorasone—Prednisone—systemic scleroderma	0.00181	0.0123	CrCrCtD
Methylprednisolone—Flunisolide—Prednisone—systemic scleroderma	0.00181	0.0123	CrCrCtD
Methylprednisolone—Fludrocortisone—Prednisone—systemic scleroderma	0.00181	0.0123	CrCrCtD
Methylprednisolone—Clobetasol propionate—Prednisone—systemic scleroderma	0.00181	0.0123	CrCrCtD
Methylprednisolone—Desonide—Prednisone—systemic scleroderma	0.00181	0.0123	CrCrCtD
Methylprednisolone—Paramethasone—Prednisone—systemic scleroderma	0.00176	0.012	CrCrCtD
Methylprednisolone—Desoximetasone—Prednisone—systemic scleroderma	0.00172	0.0117	CrCrCtD
Methylprednisolone—Fluorometholone—Prednisone—systemic scleroderma	0.00168	0.0114	CrCrCtD
Methylprednisolone—Triamcinolone—Prednisone—systemic scleroderma	0.00168	0.0114	CrCrCtD
Methylprednisolone—Mometasone—Prednisone—systemic scleroderma	0.00168	0.0114	CrCrCtD
Methylprednisolone—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00168	0.0114	CrCrCtD
Methylprednisolone—Loteprednol—Prednisone—systemic scleroderma	0.00168	0.0114	CrCrCtD
Methylprednisolone—Rimexolone—Prednisone—systemic scleroderma	0.00164	0.0111	CrCrCtD
Methylprednisolone—Betamethasone—Prednisone—systemic scleroderma	0.00164	0.0111	CrCrCtD
Methylprednisolone—Dexamethasone—Prednisone—systemic scleroderma	0.00164	0.0111	CrCrCtD
Methylprednisolone—Prednisolone—Prednisone—systemic scleroderma	0.00153	0.0104	CrCrCtD
Methylprednisolone—Hydrocortisone—Prednisone—systemic scleroderma	0.00147	0.01	CrCrCtD
Methylprednisolone—Malnutrition—Mycophenolate mofetil—systemic scleroderma	2.11e-05	0.000519	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	2.11e-05	0.000519	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Prednisone—systemic scleroderma	2.1e-05	0.000515	CcSEcCtD
Methylprednisolone—Muscular weakness—Prednisone—systemic scleroderma	2.1e-05	0.000515	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	2.09e-05	0.000512	CcSEcCtD
Methylprednisolone—Insomnia—Leflunomide—systemic scleroderma	2.07e-05	0.000509	CcSEcCtD
Methylprednisolone—Abdominal distension—Prednisone—systemic scleroderma	2.07e-05	0.000508	CcSEcCtD
Methylprednisolone—Paraesthesia—Leflunomide—systemic scleroderma	2.06e-05	0.000505	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Methotrexate—systemic scleroderma	2.05e-05	0.000504	CcSEcCtD
Methylprednisolone—Myalgia—Lisinopril—systemic scleroderma	2.05e-05	0.000504	CcSEcCtD
Methylprednisolone—Arthralgia—Lisinopril—systemic scleroderma	2.05e-05	0.000504	CcSEcCtD
Methylprednisolone—Anxiety—Lisinopril—systemic scleroderma	2.04e-05	0.000502	CcSEcCtD
Methylprednisolone—Hypotension—Mycophenolic acid—systemic scleroderma	2.04e-05	0.000501	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	2.04e-05	0.000501	CcSEcCtD
Methylprednisolone—Discomfort—Lisinopril—systemic scleroderma	2.03e-05	0.000498	CcSEcCtD
Methylprednisolone—Dyspepsia—Leflunomide—systemic scleroderma	2.01e-05	0.000495	CcSEcCtD
Methylprednisolone—Pancreatitis—Prednisone—systemic scleroderma	2.01e-05	0.000495	CcSEcCtD
Methylprednisolone—Vomiting—Mometasone—systemic scleroderma	2.01e-05	0.000494	CcSEcCtD
Methylprednisolone—Sweating increased—Prednisone—systemic scleroderma	2e-05	0.000492	CcSEcCtD
Methylprednisolone—Feeling abnormal—Azathioprine—systemic scleroderma	2e-05	0.000491	CcSEcCtD
Methylprednisolone—Rash—Mometasone—systemic scleroderma	1.99e-05	0.00049	CcSEcCtD
Methylprednisolone—Asthenia—Captopril—systemic scleroderma	1.99e-05	0.00049	CcSEcCtD
Methylprednisolone—Dermatitis—Mometasone—systemic scleroderma	1.99e-05	0.000489	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	1.99e-05	0.000489	CcSEcCtD
Methylprednisolone—Osteoarthritis—Methotrexate—systemic scleroderma	1.99e-05	0.000488	CcSEcCtD
Methylprednisolone—Confusional state—Lisinopril—systemic scleroderma	1.98e-05	0.000487	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Azathioprine—systemic scleroderma	1.98e-05	0.000487	CcSEcCtD
Methylprednisolone—Headache—Mometasone—systemic scleroderma	1.98e-05	0.000487	CcSEcCtD
Methylprednisolone—Insomnia—Mycophenolic acid—systemic scleroderma	1.97e-05	0.000485	CcSEcCtD
Methylprednisolone—Fatigue—Leflunomide—systemic scleroderma	1.97e-05	0.000485	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Lisinopril—systemic scleroderma	1.97e-05	0.000483	CcSEcCtD
Methylprednisolone—Pruritus—Captopril—systemic scleroderma	1.96e-05	0.000483	CcSEcCtD
Methylprednisolone—Paraesthesia—Mycophenolic acid—systemic scleroderma	1.96e-05	0.000482	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	1.96e-05	0.000481	CcSEcCtD
Methylprednisolone—Infection—Lisinopril—systemic scleroderma	1.95e-05	0.00048	CcSEcCtD
Methylprednisolone—Shock—Lisinopril—systemic scleroderma	1.93e-05	0.000476	CcSEcCtD
Methylprednisolone—Angioedema—Mycophenolate mofetil—systemic scleroderma	1.93e-05	0.000474	CcSEcCtD
Methylprednisolone—Dyspepsia—Mycophenolic acid—systemic scleroderma	1.92e-05	0.000472	CcSEcCtD
Methylprednisolone—Tachycardia—Lisinopril—systemic scleroderma	1.92e-05	0.000472	CcSEcCtD
Methylprednisolone—Abdominal pain—Azathioprine—systemic scleroderma	1.92e-05	0.000471	CcSEcCtD
Methylprednisolone—Skin disorder—Lisinopril—systemic scleroderma	1.91e-05	0.000469	CcSEcCtD
Methylprednisolone—Malaise—Mycophenolate mofetil—systemic scleroderma	1.9e-05	0.000468	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Lisinopril—systemic scleroderma	1.9e-05	0.000467	CcSEcCtD
Methylprednisolone—Diarrhoea—Captopril—systemic scleroderma	1.9e-05	0.000467	CcSEcCtD
Methylprednisolone—Vertigo—Mycophenolate mofetil—systemic scleroderma	1.9e-05	0.000466	CcSEcCtD
Methylprednisolone—Irritability—Methotrexate—systemic scleroderma	1.9e-05	0.000466	CcSEcCtD
Methylprednisolone—Syncope—Mycophenolate mofetil—systemic scleroderma	1.89e-05	0.000465	CcSEcCtD
Methylprednisolone—Feeling abnormal—Leflunomide—systemic scleroderma	1.89e-05	0.000464	CcSEcCtD
Methylprednisolone—Fatigue—Mycophenolic acid—systemic scleroderma	1.88e-05	0.000463	CcSEcCtD
Methylprednisolone—Mood swings—Methotrexate—systemic scleroderma	1.88e-05	0.000462	CcSEcCtD
Methylprednisolone—Nausea—Mometasone—systemic scleroderma	1.88e-05	0.000462	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Leflunomide—systemic scleroderma	1.87e-05	0.00046	CcSEcCtD
Methylprednisolone—Weight increased—Prednisone—systemic scleroderma	1.87e-05	0.000459	CcSEcCtD
Methylprednisolone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	1.86e-05	0.000456	CcSEcCtD
Methylprednisolone—Hypotension—Lisinopril—systemic scleroderma	1.84e-05	0.000452	CcSEcCtD
Methylprednisolone—Dizziness—Captopril—systemic scleroderma	1.84e-05	0.000451	CcSEcCtD
Methylprednisolone—Convulsion—Mycophenolate mofetil—systemic scleroderma	1.83e-05	0.00045	CcSEcCtD
Methylprednisolone—Hypertension—Mycophenolate mofetil—systemic scleroderma	1.82e-05	0.000448	CcSEcCtD
Methylprednisolone—Urticaria—Leflunomide—systemic scleroderma	1.82e-05	0.000447	CcSEcCtD
Methylprednisolone—Abdominal pain—Leflunomide—systemic scleroderma	1.81e-05	0.000445	CcSEcCtD
Methylprednisolone—Acute coronary syndrome—Prednisone—systemic scleroderma	1.81e-05	0.000444	CcSEcCtD
Methylprednisolone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	1.8e-05	0.000442	CcSEcCtD
Methylprednisolone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	1.8e-05	0.000442	CcSEcCtD
Methylprednisolone—Myalgia—Mycophenolate mofetil—systemic scleroderma	1.8e-05	0.000442	CcSEcCtD
Methylprednisolone—Myocardial infarction—Prednisone—systemic scleroderma	1.8e-05	0.000441	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Prednisone—systemic scleroderma	1.8e-05	0.000441	CcSEcCtD
Methylprednisolone—Breast disorder—Methotrexate—systemic scleroderma	1.79e-05	0.000441	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	1.79e-05	0.00044	CcSEcCtD
Methylprednisolone—Anxiety—Mycophenolate mofetil—systemic scleroderma	1.79e-05	0.00044	CcSEcCtD
Methylprednisolone—Hypersensitivity—Azathioprine—systemic scleroderma	1.79e-05	0.000439	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	1.79e-05	0.000439	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	1.79e-05	0.000439	CcSEcCtD
Methylprednisolone—Insomnia—Lisinopril—systemic scleroderma	1.78e-05	0.000437	CcSEcCtD
Methylprednisolone—Discomfort—Mycophenolate mofetil—systemic scleroderma	1.78e-05	0.000436	CcSEcCtD
Methylprednisolone—Paraesthesia—Lisinopril—systemic scleroderma	1.77e-05	0.000434	CcSEcCtD
Methylprednisolone—Vomiting—Captopril—systemic scleroderma	1.77e-05	0.000434	CcSEcCtD
Methylprednisolone—Rash—Captopril—systemic scleroderma	1.75e-05	0.00043	CcSEcCtD
Methylprednisolone—Dermatitis—Captopril—systemic scleroderma	1.75e-05	0.00043	CcSEcCtD
Methylprednisolone—Headache—Captopril—systemic scleroderma	1.74e-05	0.000428	CcSEcCtD
Methylprednisolone—Confusional state—Mycophenolate mofetil—systemic scleroderma	1.74e-05	0.000427	CcSEcCtD
Methylprednisolone—Dyspepsia—Lisinopril—systemic scleroderma	1.73e-05	0.000425	CcSEcCtD
Methylprednisolone—Abdominal pain—Mycophenolic acid—systemic scleroderma	1.73e-05	0.000424	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	1.72e-05	0.000423	CcSEcCtD
Methylprednisolone—Infection—Mycophenolate mofetil—systemic scleroderma	1.71e-05	0.000421	CcSEcCtD
Methylprednisolone—Fatigue—Lisinopril—systemic scleroderma	1.7e-05	0.000417	CcSEcCtD
Methylprednisolone—Shock—Mycophenolate mofetil—systemic scleroderma	1.7e-05	0.000417	CcSEcCtD
Methylprednisolone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	1.69e-05	0.000415	CcSEcCtD
Methylprednisolone—Hypersensitivity—Leflunomide—systemic scleroderma	1.69e-05	0.000414	CcSEcCtD
Methylprednisolone—Pancreatitis—Methotrexate—systemic scleroderma	1.68e-05	0.000414	CcSEcCtD
Methylprednisolone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	1.68e-05	0.000413	CcSEcCtD
Methylprednisolone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	1.67e-05	0.000411	CcSEcCtD
Methylprednisolone—Bradycardia—Prednisone—systemic scleroderma	1.67e-05	0.000411	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	1.67e-05	0.000409	CcSEcCtD
Methylprednisolone—Diarrhoea—Azathioprine—systemic scleroderma	1.66e-05	0.000408	CcSEcCtD
Methylprednisolone—Haemoglobin—Prednisone—systemic scleroderma	1.65e-05	0.000406	CcSEcCtD
Methylprednisolone—Nausea—Captopril—systemic scleroderma	1.65e-05	0.000405	CcSEcCtD
Methylprednisolone—Haemorrhage—Prednisone—systemic scleroderma	1.64e-05	0.000404	CcSEcCtD
Methylprednisolone—Asthenia—Leflunomide—systemic scleroderma	1.64e-05	0.000404	CcSEcCtD
Methylprednisolone—Hallucination—Prednisone—systemic scleroderma	1.64e-05	0.000402	CcSEcCtD
Methylprednisolone—Feeling abnormal—Lisinopril—systemic scleroderma	1.62e-05	0.000398	CcSEcCtD
Methylprednisolone—Pruritus—Leflunomide—systemic scleroderma	1.62e-05	0.000398	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Prednisone—systemic scleroderma	1.62e-05	0.000397	CcSEcCtD
Methylprednisolone—Hypotension—Mycophenolate mofetil—systemic scleroderma	1.61e-05	0.000396	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Lisinopril—systemic scleroderma	1.61e-05	0.000395	CcSEcCtD
Methylprednisolone—Dizziness—Azathioprine—systemic scleroderma	1.6e-05	0.000394	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	1.57e-05	0.000386	CcSEcCtD
Methylprednisolone—Asthenia—Mycophenolic acid—systemic scleroderma	1.57e-05	0.000385	CcSEcCtD
Methylprednisolone—Diarrhoea—Leflunomide—systemic scleroderma	1.57e-05	0.000385	CcSEcCtD
Methylprednisolone—Urticaria—Lisinopril—systemic scleroderma	1.56e-05	0.000384	CcSEcCtD
Methylprednisolone—Insomnia—Mycophenolate mofetil—systemic scleroderma	1.56e-05	0.000383	CcSEcCtD
Methylprednisolone—Abdominal pain—Lisinopril—systemic scleroderma	1.55e-05	0.000382	CcSEcCtD
Methylprednisolone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	1.55e-05	0.00038	CcSEcCtD
Methylprednisolone—Pruritus—Mycophenolic acid—systemic scleroderma	1.54e-05	0.00038	CcSEcCtD
Methylprednisolone—Vomiting—Azathioprine—systemic scleroderma	1.54e-05	0.000379	CcSEcCtD
Methylprednisolone—Eye disorder—Prednisone—systemic scleroderma	1.54e-05	0.000378	CcSEcCtD
Methylprednisolone—Infestation NOS—Methotrexate—systemic scleroderma	1.53e-05	0.000376	CcSEcCtD
Methylprednisolone—Infestation—Methotrexate—systemic scleroderma	1.53e-05	0.000376	CcSEcCtD
Methylprednisolone—Rash—Azathioprine—systemic scleroderma	1.53e-05	0.000376	CcSEcCtD
Methylprednisolone—Dermatitis—Azathioprine—systemic scleroderma	1.53e-05	0.000375	CcSEcCtD
Methylprednisolone—Headache—Azathioprine—systemic scleroderma	1.52e-05	0.000373	CcSEcCtD
Methylprednisolone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	1.52e-05	0.000373	CcSEcCtD
Methylprednisolone—Dizziness—Leflunomide—systemic scleroderma	1.51e-05	0.000372	CcSEcCtD
Methylprednisolone—Diarrhoea—Mycophenolic acid—systemic scleroderma	1.49e-05	0.000367	CcSEcCtD
Methylprednisolone—Angiopathy—Prednisone—systemic scleroderma	1.49e-05	0.000367	CcSEcCtD
Methylprednisolone—Immune system disorder—Prednisone—systemic scleroderma	1.48e-05	0.000365	CcSEcCtD
Methylprednisolone—Arrhythmia—Prednisone—systemic scleroderma	1.47e-05	0.000361	CcSEcCtD
Methylprednisolone—Sweating—Methotrexate—systemic scleroderma	1.47e-05	0.000361	CcSEcCtD
Methylprednisolone—Vomiting—Leflunomide—systemic scleroderma	1.46e-05	0.000358	CcSEcCtD
Methylprednisolone—Hypersensitivity—Lisinopril—systemic scleroderma	1.45e-05	0.000356	CcSEcCtD
Methylprednisolone—Dizziness—Mycophenolic acid—systemic scleroderma	1.44e-05	0.000355	CcSEcCtD
Methylprednisolone—Rash—Leflunomide—systemic scleroderma	1.44e-05	0.000355	CcSEcCtD
Methylprednisolone—Dermatitis—Leflunomide—systemic scleroderma	1.44e-05	0.000354	CcSEcCtD
Methylprednisolone—Mental disorder—Prednisone—systemic scleroderma	1.44e-05	0.000354	CcSEcCtD
Methylprednisolone—Nausea—Azathioprine—systemic scleroderma	1.44e-05	0.000354	CcSEcCtD
Methylprednisolone—Headache—Leflunomide—systemic scleroderma	1.43e-05	0.000352	CcSEcCtD
Methylprednisolone—Erythema—Prednisone—systemic scleroderma	1.43e-05	0.000352	CcSEcCtD
Methylprednisolone—Malnutrition—Prednisone—systemic scleroderma	1.43e-05	0.000352	CcSEcCtD
Methylprednisolone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	1.42e-05	0.000349	CcSEcCtD
Methylprednisolone—Asthenia—Lisinopril—systemic scleroderma	1.41e-05	0.000347	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	1.41e-05	0.000346	CcSEcCtD
Methylprednisolone—Pruritus—Lisinopril—systemic scleroderma	1.39e-05	0.000342	CcSEcCtD
Methylprednisolone—Vomiting—Mycophenolic acid—systemic scleroderma	1.39e-05	0.000341	CcSEcCtD
Methylprednisolone—Haemoglobin—Methotrexate—systemic scleroderma	1.38e-05	0.000339	CcSEcCtD
Methylprednisolone—Rash—Mycophenolic acid—systemic scleroderma	1.38e-05	0.000338	CcSEcCtD
Methylprednisolone—Dermatitis—Mycophenolic acid—systemic scleroderma	1.38e-05	0.000338	CcSEcCtD
Methylprednisolone—Haemorrhage—Methotrexate—systemic scleroderma	1.37e-05	0.000338	CcSEcCtD
Methylprednisolone—Urticaria—Mycophenolate mofetil—systemic scleroderma	1.37e-05	0.000336	CcSEcCtD
Methylprednisolone—Headache—Mycophenolic acid—systemic scleroderma	1.37e-05	0.000336	CcSEcCtD
Methylprednisolone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	1.36e-05	0.000335	CcSEcCtD
Methylprednisolone—Nausea—Leflunomide—systemic scleroderma	1.36e-05	0.000334	CcSEcCtD
Methylprednisolone—Diarrhoea—Lisinopril—systemic scleroderma	1.35e-05	0.000331	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Prednisone—systemic scleroderma	1.33e-05	0.000326	CcSEcCtD
Methylprednisolone—Visual impairment—Methotrexate—systemic scleroderma	1.32e-05	0.000325	CcSEcCtD
Methylprednisolone—Angioedema—Prednisone—systemic scleroderma	1.31e-05	0.000321	CcSEcCtD
Methylprednisolone—Dizziness—Lisinopril—systemic scleroderma	1.3e-05	0.00032	CcSEcCtD
Methylprednisolone—Nausea—Mycophenolic acid—systemic scleroderma	1.3e-05	0.000319	CcSEcCtD
Methylprednisolone—Malaise—Prednisone—systemic scleroderma	1.29e-05	0.000317	CcSEcCtD
Methylprednisolone—Vertigo—Prednisone—systemic scleroderma	1.29e-05	0.000316	CcSEcCtD
Methylprednisolone—Eye disorder—Methotrexate—systemic scleroderma	1.28e-05	0.000316	CcSEcCtD
Methylprednisolone—Syncope—Prednisone—systemic scleroderma	1.28e-05	0.000315	CcSEcCtD
Methylprednisolone—Cardiac disorder—Methotrexate—systemic scleroderma	1.28e-05	0.000313	CcSEcCtD
Methylprednisolone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	1.27e-05	0.000312	CcSEcCtD
Methylprednisolone—Loss of consciousness—Prednisone—systemic scleroderma	1.26e-05	0.000309	CcSEcCtD
Methylprednisolone—Vomiting—Lisinopril—systemic scleroderma	1.25e-05	0.000307	CcSEcCtD
Methylprednisolone—Angiopathy—Methotrexate—systemic scleroderma	1.25e-05	0.000306	CcSEcCtD
Methylprednisolone—Immune system disorder—Methotrexate—systemic scleroderma	1.24e-05	0.000305	CcSEcCtD
Methylprednisolone—Rash—Lisinopril—systemic scleroderma	1.24e-05	0.000305	CcSEcCtD
Methylprednisolone—Convulsion—Prednisone—systemic scleroderma	1.24e-05	0.000305	CcSEcCtD
Methylprednisolone—Dermatitis—Lisinopril—systemic scleroderma	1.24e-05	0.000304	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Methotrexate—systemic scleroderma	1.24e-05	0.000304	CcSEcCtD
Methylprednisolone—Asthenia—Mycophenolate mofetil—systemic scleroderma	1.24e-05	0.000304	CcSEcCtD
Methylprednisolone—Hypertension—Prednisone—systemic scleroderma	1.24e-05	0.000304	CcSEcCtD
Methylprednisolone—Headache—Lisinopril—systemic scleroderma	1.23e-05	0.000303	CcSEcCtD
Methylprednisolone—Pruritus—Mycophenolate mofetil—systemic scleroderma	1.22e-05	0.0003	CcSEcCtD
Methylprednisolone—Myalgia—Prednisone—systemic scleroderma	1.22e-05	0.000299	CcSEcCtD
Methylprednisolone—Arthralgia—Prednisone—systemic scleroderma	1.22e-05	0.000299	CcSEcCtD
Methylprednisolone—Anxiety—Prednisone—systemic scleroderma	1.21e-05	0.000298	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	1.21e-05	0.000297	CcSEcCtD
Methylprednisolone—Discomfort—Prednisone—systemic scleroderma	1.2e-05	0.000296	CcSEcCtD
Methylprednisolone—Mental disorder—Methotrexate—systemic scleroderma	1.2e-05	0.000296	CcSEcCtD
Methylprednisolone—Erythema—Methotrexate—systemic scleroderma	1.2e-05	0.000294	CcSEcCtD
Methylprednisolone—Malnutrition—Methotrexate—systemic scleroderma	1.2e-05	0.000294	CcSEcCtD
Methylprednisolone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	1.18e-05	0.00029	CcSEcCtD
Methylprednisolone—Nausea—Lisinopril—systemic scleroderma	1.17e-05	0.000287	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Prednisone—systemic scleroderma	1.17e-05	0.000287	CcSEcCtD
Methylprednisolone—Infection—Prednisone—systemic scleroderma	1.16e-05	0.000285	CcSEcCtD
Methylprednisolone—Shock—Prednisone—systemic scleroderma	1.15e-05	0.000282	CcSEcCtD
Methylprednisolone—Nervous system disorder—Prednisone—systemic scleroderma	1.15e-05	0.000282	CcSEcCtD
Methylprednisolone—Tachycardia—Prednisone—systemic scleroderma	1.14e-05	0.00028	CcSEcCtD
Methylprednisolone—Dizziness—Mycophenolate mofetil—systemic scleroderma	1.14e-05	0.00028	CcSEcCtD
Methylprednisolone—Skin disorder—Prednisone—systemic scleroderma	1.13e-05	0.000279	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Prednisone—systemic scleroderma	1.13e-05	0.000277	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Methotrexate—systemic scleroderma	1.11e-05	0.000273	CcSEcCtD
Methylprednisolone—Vomiting—Mycophenolate mofetil—systemic scleroderma	1.1e-05	0.000269	CcSEcCtD
Methylprednisolone—Rash—Mycophenolate mofetil—systemic scleroderma	1.09e-05	0.000267	CcSEcCtD
Methylprednisolone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	1.09e-05	0.000267	CcSEcCtD
Methylprednisolone—Headache—Mycophenolate mofetil—systemic scleroderma	1.08e-05	0.000265	CcSEcCtD
Methylprednisolone—Malaise—Methotrexate—systemic scleroderma	1.08e-05	0.000265	CcSEcCtD
Methylprednisolone—Vertigo—Methotrexate—systemic scleroderma	1.07e-05	0.000264	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	1.06e-05	0.000262	CcSEcCtD
Methylprednisolone—Insomnia—Prednisone—systemic scleroderma	1.06e-05	0.00026	CcSEcCtD
Methylprednisolone—Paraesthesia—Prednisone—systemic scleroderma	1.05e-05	0.000258	CcSEcCtD
Methylprednisolone—Convulsion—Methotrexate—systemic scleroderma	1.04e-05	0.000255	CcSEcCtD
Methylprednisolone—Dyspepsia—Prednisone—systemic scleroderma	1.03e-05	0.000253	CcSEcCtD
Methylprednisolone—Nausea—Mycophenolate mofetil—systemic scleroderma	1.02e-05	0.000252	CcSEcCtD
Methylprednisolone—Myalgia—Methotrexate—systemic scleroderma	1.02e-05	0.00025	CcSEcCtD
Methylprednisolone—Arthralgia—Methotrexate—systemic scleroderma	1.02e-05	0.00025	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	1.01e-05	0.000249	CcSEcCtD
Methylprednisolone—Fatigue—Prednisone—systemic scleroderma	1.01e-05	0.000247	CcSEcCtD
Methylprednisolone—Discomfort—Methotrexate—systemic scleroderma	1.01e-05	0.000247	CcSEcCtD
Methylprednisolone—Confusional state—Methotrexate—systemic scleroderma	9.84e-06	0.000242	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Methotrexate—systemic scleroderma	9.76e-06	0.00024	CcSEcCtD
Methylprednisolone—Infection—Methotrexate—systemic scleroderma	9.7e-06	0.000238	CcSEcCtD
Methylprednisolone—Feeling abnormal—Prednisone—systemic scleroderma	9.62e-06	0.000237	CcSEcCtD
Methylprednisolone—Nervous system disorder—Methotrexate—systemic scleroderma	9.57e-06	0.000235	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Prednisone—systemic scleroderma	9.55e-06	0.000235	CcSEcCtD
Methylprednisolone—Skin disorder—Methotrexate—systemic scleroderma	9.48e-06	0.000233	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Methotrexate—systemic scleroderma	9.44e-06	0.000232	CcSEcCtD
Methylprednisolone—Urticaria—Prednisone—systemic scleroderma	9.28e-06	0.000228	CcSEcCtD
Methylprednisolone—Abdominal pain—Prednisone—systemic scleroderma	9.23e-06	0.000227	CcSEcCtD
Methylprednisolone—Hypotension—Methotrexate—systemic scleroderma	9.12e-06	0.000224	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	8.89e-06	0.000219	CcSEcCtD
Methylprednisolone—Insomnia—Methotrexate—systemic scleroderma	8.83e-06	0.000217	CcSEcCtD
Methylprednisolone—Paraesthesia—Methotrexate—systemic scleroderma	8.77e-06	0.000215	CcSEcCtD
Methylprednisolone—Hypersensitivity—Prednisone—systemic scleroderma	8.61e-06	0.000211	CcSEcCtD
Methylprednisolone—Dyspepsia—Methotrexate—systemic scleroderma	8.59e-06	0.000211	CcSEcCtD
Methylprednisolone—Fatigue—Methotrexate—systemic scleroderma	8.42e-06	0.000207	CcSEcCtD
Methylprednisolone—Asthenia—Prednisone—systemic scleroderma	8.38e-06	0.000206	CcSEcCtD
Methylprednisolone—Pruritus—Prednisone—systemic scleroderma	8.26e-06	0.000203	CcSEcCtD
Methylprednisolone—Feeling abnormal—Methotrexate—systemic scleroderma	8.04e-06	0.000198	CcSEcCtD
Methylprednisolone—Diarrhoea—Prednisone—systemic scleroderma	7.99e-06	0.000196	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Methotrexate—systemic scleroderma	7.98e-06	0.000196	CcSEcCtD
Methylprednisolone—Urticaria—Methotrexate—systemic scleroderma	7.75e-06	0.000191	CcSEcCtD
Methylprednisolone—Dizziness—Prednisone—systemic scleroderma	7.72e-06	0.00019	CcSEcCtD
Methylprednisolone—Abdominal pain—Methotrexate—systemic scleroderma	7.72e-06	0.00019	CcSEcCtD
Methylprednisolone—Vomiting—Prednisone—systemic scleroderma	7.43e-06	0.000183	CcSEcCtD
Methylprednisolone—Rash—Prednisone—systemic scleroderma	7.36e-06	0.000181	CcSEcCtD
Methylprednisolone—Dermatitis—Prednisone—systemic scleroderma	7.36e-06	0.000181	CcSEcCtD
Methylprednisolone—Headache—Prednisone—systemic scleroderma	7.32e-06	0.00018	CcSEcCtD
Methylprednisolone—Hypersensitivity—Methotrexate—systemic scleroderma	7.19e-06	0.000177	CcSEcCtD
Methylprednisolone—Asthenia—Methotrexate—systemic scleroderma	7e-06	0.000172	CcSEcCtD
Methylprednisolone—Nausea—Prednisone—systemic scleroderma	6.94e-06	0.000171	CcSEcCtD
Methylprednisolone—Pruritus—Methotrexate—systemic scleroderma	6.91e-06	0.00017	CcSEcCtD
Methylprednisolone—Diarrhoea—Methotrexate—systemic scleroderma	6.68e-06	0.000164	CcSEcCtD
Methylprednisolone—Dizziness—Methotrexate—systemic scleroderma	6.45e-06	0.000159	CcSEcCtD
Methylprednisolone—Vomiting—Methotrexate—systemic scleroderma	6.21e-06	0.000153	CcSEcCtD
Methylprednisolone—Rash—Methotrexate—systemic scleroderma	6.15e-06	0.000151	CcSEcCtD
Methylprednisolone—Dermatitis—Methotrexate—systemic scleroderma	6.15e-06	0.000151	CcSEcCtD
Methylprednisolone—Headache—Methotrexate—systemic scleroderma	6.12e-06	0.00015	CcSEcCtD
Methylprednisolone—Nausea—Methotrexate—systemic scleroderma	5.8e-06	0.000142	CcSEcCtD
